Company Description
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States.
The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms.
The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS.
In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease.
Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine.
It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers.
The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019.
Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
| Country | United States |
| IPO Date | Sep 19, 2019 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 174 |
| CEO | John Aballi |
Contact Details
Address: 1261 Liberty Way Vista, California 92081 United States | |
| Phone | (760) 560-1501 |
| Website | exagen.com |
Stock Details
| Ticker Symbol | XGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001274737 |
| CUSIP Number | 30068X103 |
| ISIN Number | US30068X1037 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| John Aballi | Chief Executive Officer, President and Director |
| Dr. Tina S. Nova Ph.D. | Executive Chairman of the Board of Directors |
| Kamal Adawi M.S., MBA | Chief Financial Officer and Corporate Secretary |
| Ryan Douglas | Investors Relations Officer |
| John Wegener | Senior Vice President of Sales and Marketing |
| Dr. Andrew L. Concoff FACR, M.D. | Chief Innovation Officer and Member of Rheumatoid Arthritis Scientific Advisory Board |
| Dr. Michael I. Nerenberg M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 11, 2024 | 8-K | Current Report |
| May 13, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | 8-K | Current Report |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 18, 2024 | 10-K | Annual Report |
| Mar 18, 2024 | 8-K | Current Report |